Welcome to our dedicated page for Sera Prognostics news (Ticker: SERA), a resource for investors and traders seeking the latest updates and insights on Sera Prognostics stock.
Sera Prognostics, Inc. (SERA) delivers innovative diagnostic solutions for pregnancy complications through advanced biomarker technology. This news hub provides investors and healthcare professionals with essential updates on clinical developments, strategic partnerships, and regulatory milestones shaping maternal health diagnostics.
Access authoritative reporting on SERA's progress in precision medicine, including trial results for preterm birth prediction tests and collaborations with leading research institutions. Our curated news collection simplifies tracking of material events influencing the company's position in the $50B+ prenatal diagnostics market.
Key updates include FDA submissions for novel tests, peer-reviewed study publications, and commercial expansion initiatives. All content undergoes rigorous fact-checking to ensure compliance with financial disclosure standards while maintaining clinical accuracy.
Bookmark this page for real-time alerts on earnings announcements, intellectual property developments, and leadership changes. Stay informed about SERA's contributions to reducing neonatal complications through early intervention strategies validated by clinical evidence.
Sera Prognostics, Inc. (NASDAQ: SERA) published data showing improved performance of its PreTRM® test for predicting spontaneous preterm birth. The study demonstrated an 88% sensitivity and 99% negative predictive value, indicating increased accuracy and reliability. The test can now be performed more conveniently during pregnancy, enhancing access for women at risk. These findings were published in the Journal of Clinical Medicine and align with updated ACOG gestational age guidelines, emphasizing Sera's commitment to improving maternal health.
Sera Prognostics (Nasdaq: SERA) presented data on the PreTRM® test-and-treat strategy at the ISPOR 2022 conference in Washington, DC. The study analyzed the effects of two intervention strategies on high-risk pregnancies using the PreTRM® Test. Results showed a significant reduction in neonatal hospital stays by 22% and maternal stays by 8.5%. Furthermore, moderate-to-severe neonatal morbidity dropped by 29%. The findings highlight the economic benefits and potential cost savings of proactive interventions in pregnancy care.
Sera Prognostics (Nasdaq: SERA) reported its Q1 2022 financial results, showing revenue of $38,000, up from $13,000 in Q1 2021. Operating expenses surged to $12.3 million, compared to $6.0 million a year earlier. The net loss increased to $12.2 million from $6.4 million. The company ended the quarter with approximately $64.1 million in cash and equivalents. Key highlights included a streamlined PreTRM® test ordering process and advancing clinical studies. The ongoing PRIME study aims to enhance neonatal outcomes and reduce healthcare costs.
Sera Prognostics, Inc. (NASDAQ: SERA) and the Newborn Foundation have partnered to launch the Every Mother, Every Baby Project aimed at reducing maternal and neonatal mortality linked to preterm birth. This initiative focuses on educating healthcare professionals and improving access to biomarker-based tests like Sera's PreTRM® test, crucial for identifying at-risk pregnancies. The project aims for equitable health outcomes by addressing policy frameworks and ensuring standardized testing reimbursement. Over 60% of infant deaths occur during the neonatal period, with preterm birth a significant contributor.
Sera Prognostics, Inc., the Pregnancy Company® (Nasdaq: SERA), will release its first quarter fiscal year 2022 financial results on May 10, 2022, after market close. A conference call and live webcast will follow at 5:00 p.m. ET to discuss operational highlights and financial metrics. Sera specializes in maternal and neonatal health through innovative diagnostics like the PreTRM® test, which predicts preterm birth risk. The company aims to improve pregnancy outcomes and reduce healthcare costs associated with complications of prematurity.
Sera Prognostics announced the appointment of Dr. Jane F. Barlow to its Board of Directors, effective April 12, 2022. Dr. Barlow is recognized for her executive experience in health services and consulting, including roles as CEO of her own firm and Chief Clinical Officer at Real Endpoints. Her expertise is expected to bolster Sera's mission to enhance maternal and neonatal health with innovative diagnostics, including the PreTRM® test, which identifies preterm birth risk. CEO Gregory C. Critchfield highlighted Dr. Barlow's potential contributions towards improving healthcare outcomes and reducing costs.
Sera Prognostics Inc. (SERA) reported its Q4 and full-year 2021 financial results, highlighting a revenue increase to $26,000 in Q4 2021 from $6,000 in Q4 2020 and $82,000 for the full year compared to $25,000 in 2020. Operating expenses rose significantly, totaling $12.6 million in Q4, primarily due to increased commercial operations and R&D costs. The company reported a net loss of $12.5 million for Q4 2021, up from $5.4 million in the previous year. Sera also announced new partnerships and ongoing market expansion efforts aimed at improving the adoption of its PreTRM® Test.
Sera Prognostics (Nasdaq: SERA) presented findings at the 69th Annual Meeting of the Society for Reproductive Investigation. The study analyzed over 10,500 patients to evaluate the prediction of preeclampsia using 31 protein biomarkers and 6 clinical factors. Key results showed that previous preeclampsia was a strong predictor, while 7 biomarkers effectively predicted preeclampsia and 5 predicted preterm preeclampsia. The study highlights Sera's commitment to improving maternal health through innovative diagnostics.
Sera Prognostics (Nasdaq: SERA), dedicated to enhancing maternal and neonatal health, will release its fourth quarter and full year 2021 financial results on March 29, 2022, post-market close. A conference call will follow at 5:00 p.m. ET to discuss the results and operational highlights. The PreTRM® Test, a key product, predicts preterm birth risk with a focus on reducing healthcare costs associated with prematurity. The company highlights its commitment to addressing the serious issue of preterm births, which affect over one in ten infants.
Sera Prognostics, dedicated to enhancing maternal and neonatal health, will present at two upcoming virtual conferences: the 42nd Annual Cowen Health Care Conference on March 8, 2022, and the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022. CEO Gregory C. Critchfield will share company updates and latest achievements. The presentations will be accessible via webcast on the Sera Prognostics website. The company focuses on early prediction of preterm birth risks through its PreTRM® Test, aiming to improve healthcare outcomes for women and infants.
